Achieving equitable access to incretin-based therapies in cardiovascular care

被引：0
|
作者：
Reddy, Tina K. [1 ]
Villavaso, Chloe D. [2 ]
Pulapaka, Anuhya V. [2 ]
Ferdinand, Keith C. [2 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD USA
[2] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA
来源：
AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE | 2024年 / 46卷
关键词：
Incretin-based therapy; Obesity; Diabetes; Hypertension; Cardiovascular disease; Racial/ethnic disparities; PREVENTION; WEIGHT;
D O I：
10.1016/j.ahjo.2024.100455
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, in the management of type 2 diabetes mellitus (T2DM) and obesity has been increasingly recognized, along with significant cardiovascular (CV) benefits. Despite the clinical efficacy of incretin-based therapies, high costs, suboptimal access, limited insurance coverage, and therapeutic inertia present substantial barriers to widespread adoption. Overcoming these obstacles is essential for the equitable initiation, access, and utilization of incretin-based therapies. Clinicians must make targeted efforts to ensure health equity in the use of these and other advanced therapies.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Impact of Incretin-Based Therapies on Adipokines and Adiponectin
    Yaribeygi, Habib
    Maleki, Mina
    Atkin, Stephen L.
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    JOURNAL OF DIABETES RESEARCH, 2021, 2021
  • [32] Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials
    Kyriakos, Georgios
    Quiles-Sanchez, Lourdes, V
    Garmpi, Anna
    Farmaki, Paraskevi
    Kyre, Konstantina
    Gkogkos, Spyridon
    Savvanis, Spyridon
    Memi, Eleni
    CURRENT CARDIOLOGY REVIEWS, 2020, 16 (04) : 253 - 257
  • [33] Incretin-Based Therapies Viewpoints on the way to consensus
    Nauck, Michael A.
    Vilsboll, Tina
    Gallwitz, Baptist
    Garber, Alan
    Madsbad, Sten
    DIABETES CARE, 2009, 32 : S223 - S231
  • [34] The role of incretin-based therapies in prediabetes: A review
    Ahmadieh, Hala
    Azar, Sami T.
    PRIMARY CARE DIABETES, 2014, 8 (04) : 286 - 294
  • [35] Effects of incretin-based therapies on renal function
    Tsimihodimos, Vasilis
    Elisaf, Moses
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 818 : 103 - 109
  • [36] Incretin-based therapies linked to pancreatic cancer?
    Reactions Weekly, 2016, 1626 (1) : 5 - 5
  • [37] Incretin-based therapies and a potential drug interaction
    Gabb, G. M.
    Smith, W.
    INTERNAL MEDICINE JOURNAL, 2011, 41 (12) : 848 - 848
  • [38] Incretin-based Therapies for Type 2 Diabetes
    McIntosh, Christopher H. S.
    CANADIAN JOURNAL OF DIABETES, 2008, 32 (02) : 131 - 139
  • [39] Incretin-Based Therapies: Revisiting Their Mode of Action
    Layden, Brian T.
    Wicksteed, Barton
    Mauvais-Jarvis, Franck
    ENDOCRINOLOGY, 2017, 158 (06) : 1560 - 1563
  • [40] Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin
    Zinman, B.
    Gough, S.
    Pratley, R.
    Brett, J.
    Lund, N.
    Buse, J.
    DIABETOLOGIA, 2011, 54 : S324 - S324
12345